MCID: PDT040
MIFTS: 29

Pediatric Hypertension

Categories: Rare diseases

Aliases & Classifications for Pediatric Hypertension

MalaCards integrated aliases for Pediatric Hypertension:

Name: Pediatric Hypertension 53

Classifications:



Summaries for Pediatric Hypertension

MalaCards based summary : Pediatric Hypertension is related to kidney disease and posterior urethral valves. An important gene associated with Pediatric Hypertension is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Ramipril and protease inhibitors have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and heart.

Related Diseases for Pediatric Hypertension

Graphical network of the top 20 diseases related to Pediatric Hypertension:



Diseases related to Pediatric Hypertension

Symptoms & Phenotypes for Pediatric Hypertension

Drugs & Therapeutics for Pediatric Hypertension

Drugs for Pediatric Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ramipril Approved Phase 4 87333-19-5 5362129
2
protease inhibitors Phase 4,Phase 3
3 HIV Protease Inhibitors Phase 4,Phase 3
4 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3
5 Antihypertensive Agents Phase 4,Phase 3,Phase 2
6
Enalaprilat Approved Phase 3 76420-72-9 6917719
7
Valsartan Approved, Investigational Phase 3 137862-53-4 60846
8
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
9
Metoprolol Approved, Investigational Phase 3 37350-58-6, 51384-51-1 4171
10
Angiotensin II Approved, Investigational Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
11
Candesartan cilexetil Approved Phase 3 145040-37-5 2540
12
Losartan Approved Phase 3,Phase 2 114798-26-4 3961
13
Candesartan Experimental Phase 3 139481-59-7 2541
14 Adrenergic Agents Phase 3
15 Adrenergic Antagonists Phase 3
16 Adrenergic beta-1 Receptor Antagonists Phase 3
17 Adrenergic beta-Antagonists Phase 3
18 Sympatholytics Phase 3
19 Neurotransmitter Agents Phase 3
20 Angiotensin II Type 1 Receptor Blockers Phase 3,Phase 2
21 Angiotensin Receptor Antagonists Phase 3,Phase 2
22 Angiotensinogen Phase 3,Phase 2
23 Anti-Arrhythmia Agents Phase 3,Phase 2
24 Peripheral Nervous System Agents Phase 3
25 Pharmaceutical Solutions Phase 3
26 Autonomic Agents Phase 3

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Treatment of Pediatric Hypertension With Altace Trial Completed NCT00044265 Phase 4 ramipril
2 N-of-1 Trials In Children With Hypertension Recruiting NCT03461003 Phase 4 Amlodipine;Lisinopril;Hydrochlorothiazide;Losartan
3 A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension Completed NCT00171028 Phase 3 valsartan
4 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension Completed NCT02451150 Phase 3 Azilsartan
5 Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age Completed NCT00244634 Phase 3 candsartan cilexetil
6 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD Completed NCT01617681 Phase 3 VAL489;VAL489 matching placebo
7 Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed NCT00255528 Phase 3 metoprolol succinate
8 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed NCT00255502 Phase 3 metoprolol succinate
9 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Completed NCT00244621 Phase 3 candesartan cilexetil (Atacand);candesartan cilexetil (Atacand);candesartan cilexetil (Atacand)
10 Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age Completed NCT00244595 Phase 3 candsartan cilexetil
11 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01150357 Phase 3 Aliskiren (6.25/12.5/25 mg);Aliskiren (37.5/75/150 mg);Aliskiren (150/300/600 mg)
12 A Study Of Valsartan Used To Treat Hypertension For Up To 13 Months In Hypertensive Children Ages 6 - 16 Years Of Age Completed NCT00171041 Phase 3 valsartan
13 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed NCT01151410 Phase 3 Aliskiren;Enalapril
14 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension Recruiting NCT02791438 Phase 3 TAK-536 2.5 mg;TAK-536 5 mg
15 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension Recruiting NCT02235909 Phase 3 Azilsartan Medoxomil;Losartan;Placebo for Azilsartan Medoxomil;Placebo for Losartan
16 Preventing Sickle Cell Kidney Disease Recruiting NCT02373241 Phase 2 Losartan;Losartan
17 A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension Withdrawn NCT00528827 Phase 2 Cardene® I.V.
18 Improving Outcomes for Hypertensive Children Completed NCT01485783
19 Ewha Birth and Growth Study (Birth Cohort) Active, not recruiting NCT03351595
20 Pediatric Hypertension Registry (PHREG) Enrolling by invitation NCT03305562

Search NIH Clinical Center for Pediatric Hypertension

Genetic Tests for Pediatric Hypertension

Anatomical Context for Pediatric Hypertension

MalaCards organs/tissues related to Pediatric Hypertension:

41
Kidney, Testes, Heart

Publications for Pediatric Hypertension

Articles related to Pediatric Hypertension:

(show top 50) (show all 124)
# Title Authors Year
1
Cardiac and Vascular Target Organ Damage in Pediatric Hypertension. ( 29881718 )
2018
2
Clinical Implications of the Revised AAP Pediatric Hypertension Guidelines. ( 29976572 )
2018
3
Changes in the 2017 Pediatric Hypertension Clinical Guidelines. ( 29087430 )
2017
4
Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 28553631 )
2017
5
Adverse Outcomes in Pediatric Hypertension. ( 29084875 )
2017
6
Commentary: Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review. ( 29164085 )
2017
7
Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary? ( 28077857 )
2017
8
Can Pediatric Hypertension Criteria Be Simplified? A Prediction Analysis of Subclinical Cardiovascular Outcomes From the Bogalusa Heart Study. ( 28223474 )
2017
9
Hypertension Canada's 2017 Guidelines for the Diagnosis,A Assessment, Prevention, and Treatment ofA Pediatric Hypertension. ( 28449829 )
2017
10
Primary Pediatric Hypertension: Current Understanding and Emerging Concepts. ( 28780627 )
2017
11
Pediatric Hypertension: Provider Perspectives. ( 28620629 )
2017
12
In-Clinic Blood Pressure Prediction of Normal Ambulatory Blood Pressure Monitoring in Pediatric Hypertension Referrals. ( 27205889 )
2016
13
Re: Pediatric Hypertension and Cardiac Hypertrophy. ( 26739585 )
2016
14
Pharmacologic Treatment of Pediatric Hypertension. ( 27048353 )
2016
15
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, and Assessment of Risk of Pediatric Hypertension. ( 27118292 )
2016
16
Pharmacologic Management of Pediatric Hypertension. ( 26597490 )
2016
17
Vascular Aging: Lessons From Pediatric Hypertension. ( 27040097 )
2016
18
Pediatric Hypertension: Are Pediatricians Following Guidelines? ( 27659546 )
2016
19
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27643063 )
2016
20
Diagnosis and Medication Treatment of Pediatric Hypertension: A Retrospective Cohort Study. ( 27940711 )
2016
21
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27643136 )
2016
22
OS 26-05 HOW TO ACCURATELY DEFINE PEDIATRIC HYPERTENSION: A SYSTEMATIC REVIEW. ( 27754136 )
2016
23
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27643124 )
2016
24
ED 08-3 APPLICATION OF ABP MONITORING IN THE MANAGEMENT OF PEDIATRIC HYPERTENSION. ( 27754179 )
2016
25
SY 13-2 LONG-TERM CARDIOVASCULAR RISK REDUCTION IN PEDIATRIC HYPERTENSION. ( 27754169 )
2016
26
Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension. ( 26988578 )
2016
27
Pediatric hypertension: a pharmacological review. ( 25898873 )
2015
28
Racial Differences of Pediatric Hypertension in Relation to Birth Weight and Body Size in the United States. ( 26176843 )
2015
29
Pediatric hypertension in the Eastern Province of Saudi Arabia. ( 25987114 )
2015
30
Pediatric hypertension: a growing problem. ( 25634711 )
2015
31
Hypertension editors' picks: pediatric hypertension. ( 25855321 )
2015
32
Diagnosis of primary versus secondary pediatric hypertension. ( 25594296 )
2015
33
The relationship between currently recommended ambulatory systolic blood pressure measures and left ventricular mass index in pediatric hypertension. ( 25794952 )
2015
34
Is Daytime Systolic Load an Important Risk Factor for Target Organ Damage in Pediatric Hypertension? ( 26140344 )
2015
35
Cardiovascular target organ damage could have been detected in sustained pediatric hypertension. ( 26024395 )
2015
36
Pediatric hypertension: a pharmacological review. ( 25898872 )
2015
37
Recent clinical and translational advances in pediatric hypertension. ( 25712720 )
2015
38
Abnormalities of vascular structure and function in pediatric hypertension. ( 26275663 )
2015
39
Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity. ( 26389821 )
2015
40
Response to &amp;quot;U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms?&amp;quot;. ( 24720549 )
2014
41
Essential pediatric hypertension: defining the educational needs of primary care pediatricians. ( 25063988 )
2014
42
Pediatric Hypertension Specialists' Perspectives About Adolescent Hypertension Management: Implications for Primary Care Providers. ( 25398627 )
2014
43
Autonomic nervous system dysregulation in pediatric hypertension. ( 24633841 )
2014
44
Pediatric hypertension: An update on a burning problem. ( 24944755 )
2014
45
Clinical predictors and impact of ambulatory blood pressure monitoring in pediatric hypertension referrals. ( 25065681 )
2014
46
Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. ( 27129124 )
2014
47
Gene polymorphisms of adducin GLY460TRP, ACE I/D, AND AGT M235T in pediatric hypertension patients. ( 25262176 )
2014
48
Pediatric hypertension: often missed and mismanaged. ( 24701598 )
2014
49
U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms? ( 24720583 )
2014
50
Executive Function and Cerebrovascular Reactivity in Pediatric Hypertension. ( 23877480 )
2013

Variations for Pediatric Hypertension

Expression for Pediatric Hypertension

Search GEO for disease gene expression data for Pediatric Hypertension.

Pathways for Pediatric Hypertension

GO Terms for Pediatric Hypertension

Biological processes related to Pediatric Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.43 ACE AGT
2 regulation of blood pressure GO:0008217 9.4 ACE AGT
3 positive regulation of protein tyrosine kinase activity GO:0061098 9.37 ACE AGT
4 blood vessel remodeling GO:0001974 9.32 ACE AGT
5 regulation of vasoconstriction GO:0019229 9.26 ACE AGT
6 angiotensin maturation GO:0002003 9.16 ACE AGT
7 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 8.96 ACE AGT
8 regulation of renal output by angiotensin GO:0002019 8.62 ACE AGT

Sources for Pediatric Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....